77 / 89
77
Raynaud's phenomenon secondary to systemic
sclerosis. J Rheumatol 2009;36:2264-8.
72.
De La Veja AJ, Derk CT. Phosphodiesterase-5
inhibitors for the treatment of Raynaud's: a
novel indication. Expert Opin Invest Drugs
2009;18:23-9.
73.
Herrick AL, van den Hoogen F, Gabrielli A,
Tamimi N, Reid C, O'Connell D, et al. Modified-
release
sildenafil
reduces
Raynaud's
phenomenon attack frequency in limited
cutaneous systemic sclerosis. Arthritis Rheum
2011;63:775-82.
74.
Pope J, Fenlon D, Thompson A, Shea B, Furst D,
Wells G, Silman A. Cyclofenil for Raynaud's
phenomenon in progressive systemic sclerosis.
Cochrane Database Syst Rev 2000;(2):CD000955.
75.
Lukác J, Rovenský J, Tauchmannová H, Zitnan
D. Effect of ketanserin on Raynaud's
phenomenon in progressive systemic sclerosis: a
double-blind trial. Drugs Exp Clin Res
1985;11:659-63.
76.
Abou-Raya A, Abou-Raya S, Helmii M. Statins:
potentially useful in therapy of systemic
sclerosis-related Raynaud's phenomenon and
digital ulcers. J Rheumatol 2008;35:1801-8.
77.
Herrick AL, Hollis S, Schofield D, Rieley F,
Blann A, Griffin K, et al. A double-blind
placebo-controlled trial of antioxidant therapy
in limited cutaneous systemic sclerosis. Clin Exp
Rheumatol 2000;18:349-56.